Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Denaverine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.47 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.47 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.47 |
| ▸ | CHRM4 known ✓ | P08173 | 3/20 | 0.45 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.45 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.43 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.43 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.43 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Denaverine SCHEMBL147346 | 0.99 | CYP3A4 (0.52) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| Dimenoxadol SCHEMBL2886211 | 0.86 | CYP3A4 (0.70) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| Dimenoxadol SCHEMBL79044 | 0.86 | CYP3A4 (0.70) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| Dimenoxadol SCHEMBL5854258 | 0.85 | CYP3A4 (0.69) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| Dimenoxadol SCHEMBL25993 | 0.84 | CYP3A4 (0.68) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| Dimenoxadol SCHEMBL2204879 | 0.84 | CYP3A4 (0.67) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| SCHEMBL29519508 | 0.81 | CYP3A4 (0.46) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| Pargeverine SCHEMBL30728632 | 0.80 | CYP3A4 (0.53) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL1649776 | 0.79 | MEN1 (0.53) | CYP3A4CYP2D6MEN1KMT2APOLB | |
| Pargeverine SCHEMBL2111437 | 0.79 | CYP3A4 (0.51) | CYP3A4CYP2D6MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117185943-A | Compound and preparation method thereof | 天津市中升挑战生物科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-11814408-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | NICOX OPHTHALMICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-113061095-B | Synthesis method of dinavilin hydrochloride | 宁波三生生物科技股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| US-20210300963-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | NICOX OPHTHALMICS, INC. | 2021-09-30 | — | — | US | disclosed |
| CN-113061095-A | Synthesis method of dinavilin hydrochloride | 宁波三生生物科技有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-10954263-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | Nicox Ophthalmics, Inc (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3741772-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | Nicox Ophthalmics, Inc. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3517541-A1 | POLYMORPHIC FORM OF FLUTICASONE PROPIONATE | Nicox Ophthalmics, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-20190169224-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | Nicox Ophthalmics, Inc | 2019-06-06 | — | — | US | disclosed |
| US-10174071-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | NICOX OPHTHALMICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180022775-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | ACIEX THERAPEUTICS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-9822142-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | NICOX OPHTHALMICS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9815865-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | NICOX OPHTHALMICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20150337006-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | ACIEX THERAPEUTICS, INC. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150126483-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | NICOX OPHTHALMICS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8765725-B2 | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof | ACIEX THERAPEUTICS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20140170157-A1 | METHOD OF SELECTING THERAPEUTIC INDICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-06-19 | — | — | US | disclosed |
| US-20130303502-A1 | Preparations of Hydrophobic Therapeutic Agents, Methods of Manufacture and Use Thereof | ACIEX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| EP-0537608-A2 | Process for the technical preparation of 2,2-diphenyl-2-(2-ethyl-butoxy)acetic acid, 2-dimethyl-amino-ethyl ester, hydrochloride | APOGEPHA ARZNEIMITTEL GmbH (DE) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170157-A1 | METHOD OF SELECTING THERAPEUTIC INDICATIONS | TSG101, TPMT, HLA-DRB1 | GAA 574/4885CHRM1 3380/4885CHRM2 1414/4885 |
| US-20150337006-A1 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF | TSLP, LIPA, IL5 | GAA 1817/4885CHRM1 430/4885CHRM2 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.